Lundbeck rolls out Brintellix in first EU country; Merck KGaA strikes emerging markets deal with Lupin;

@FiercePharma: Top-read in FierceAnimalHealth Mon: FDA seeks input on conditional approvals for new animal health products. Story | Follow @FiercePharma

@EricPFierce: Merck KGaA turns to India's Lupin to manufacture $2B worth of drugs in emerging markets. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them. ICYMI yesterday | Follow @CarlyHFierce

> The Danish drugmaker Lundbeck launched its new antidepressant Brintellix in its home market, its first roll-out for the new drug in the EU. Report

> Merck KGaA inked a deal with India's Lupin to sell its generic drugs in emerging markets. Report

> The only company making smallpox treatments for U.S. stockpiles, Siga Technologies, filed for bankruptcy to forestall a $232 million damages award to competitor PharmAthene. Report

> Bristol-Myers Squibb's ($BMY) Yervoy won approval in Canada as a first-line treatment for advanced melanoma. Release

> European regulators said they would rule by Oct. 16 on AbbVie's ($ABBV) proposed $52 billion buyout of the Irish drugmaker Shire ($SHPG). Report

> Germany's Stada reaffirmed its prediction that its Russian business, which accounts for about one-fourth of its sales, would take a turn for the better in the fourth quarter. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Danaher cements commitment to dental with $2.2B Nobel acquisition. Article | Follow @FierceMedDev

@MichaelGFierce: Liposome research adds up to better #cancer treatment options. More | Follow @MichaelGFierce

> WSJ: What are the costs and benefits of early cancer screening? Item

> Harvard researchers develop dialysis device to fight Ebola. Story

> Former Alere execs assemble $3.8B take-private offer. Report

Biotech News

@FierceBiotech: Lilly takes the lead on AstraZeneca's Alzheimer's drug in $500M deal. News | Follow @FierceBiotech

@JohnCFierce: Biotech R&D is changing. Don't get left behind. (A shameless plug for upcoming executive breakfast panel in Boston). More | Follow @JohnCFierce

@DamianFierce: Oxygen Bio will soon be Tenax Therapeutics. Release | Follow @DamianFierce

@EmilyMFierce: Great piece on the trials and tribulations of stem cell research. Report from the NYT | Follow @EmilyMFierce

> U.K. picks a controversial brain cancer vaccine as its first new 'innovative medicine.' Story

> Novo's next-gen insulin clears a pediatric hurdle amid renewed U.S. hope. Article

> Smallpox biotech Siga files for bankruptcy over PharmAthene spat. Item

> Parkinson's biotech NeuroDerm joins the IPO queue with a $65M pitch. More

Biotech Research News

> Notable academic-pharma alliances of 2014. Feature

> Geneva Foundation gets $3M NIH grant for Ebola drug work. News

> Protein stops bone loss in arthritic mice. More

> Google's Calico acquires UT Southwestern compounds for neurodegenerative disorders. Story

> $64M NIH initiative will catalog cell responses to drugs. Article

Pharma Manufacturing News

> Gilead hands Sovaldi manufacturing tech to 7 generics makers. Report

> Merck negotiates huge production deal with Lupin. More

> Hikma opens oncology API plant in Jordan. Article

> India's top drugmakers forecast to invest $8B in production upgrades. Item

> Hospira again reports a human hair discovered in a product. Story

And Finally... The Ropes & Gray law firm's Hong Kong office, which represents GlaxoSmithKline ($GSK) and other big drugmakers, hired an assistant U.S. attorney to help clients understand "how U.S. prosecutors" and regulators are thinking. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.